혈관 폐쇄 기기 시장 보고서 : 제품별, 접근법별, 시술별, 최종 사용자별, 지역별(2026-2034년)

The global vascular closure devices market size reached USD 1.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.71% during 2026-2034. North America currently is the leading region due to the well-developed healthcare infrastructure, burgeoning healthcare expenditure, and increased incidence of cardiovascular disorders. Moreover, the increasing prevalence of cardiovascular disease (CVDs), rising vascular procedures, technological advancements in closure devices, aging population demographics favoring minimally invasive (MI) treatments, expanding healthcare expenditure in emerging markets, and ongoing innovation efforts are some of the factors stimulating the market expansion.

VASCULAR CLOSURE DEVICES MARKET ANALYSIS:

• Major Market Drivers: The growing adoption of catheterization procedures for the treatment of coronary artery disease and the increasing prevalence of cardiovascular diseases (CVDs) are the major factors driving the growth of the vascular closure devices market growth. The innovation in minimally invasive (MI) surgeries increases the adoption of such devices due to shorter recovery time and complications, which is boosting the market growth. Additionally, growing geriatric population prone to vascular diseases and the surging number of obese patients around the world have led to a higher incidence of CVDs, which, in turn, is accelerating the market growth. Additionally, the availability of advanced health care infrastructure, particularly in the developing countries, for non-surgical but advanced procedures like using vascular closure devices, is another growth-inducing factor. Moreover, the vascular closure devices market share is propelled by the increasing demand for diagnostic and therapeutic procedures, which are non-invasive and allow patient comfort and eliminate the likelihood of fast ambulation post-surgery.
• Key Market Trends: Rapid innovation is one of the prominent drivers in the vascular closure devices market which has led to the growth of user-friendly devices. Moreover, the shifting preference towards bioresorbable or absorbable devices that aid to reduce risk of long-term complications and negate the need for device removal. Furthermore, active closure devices are increasingly being adopted in the market as they offer immediate hemostasis. Apart from this, personalized medicine is also gaining popularity as they are customizable to the patient's individual condition and anatomy. Apart from this, technology advancements have paved way to the development of telemedicine and remote monitoring, which are incorporating with post-procedural care leading to improved patient management after vascular closures, which is another key vascular closure devices market trends.
• Geographical Trends: Regionally, North America is the most lucrative marketplace for the global vascular closure devices market on account of a well-developed healthcare infrastructure, burgeoning healthcare expenditure, and increased incidence of cardiovascular disorders. The market is competitive with strong regulatory support for medical devices by governments & research and development (R&D) Investments in the region. Europe is right behind with their steady progression towards advanced technologies and supportive healthcare policies. However, Asia-Pacific is expected to experience the highest rate of growth because of improved healthcare infrastructure, a growing number of medical tourism facilities in developing economies, and increased awareness of MI techniques.
• Competitive Landscape: The competitive landscape of the market is characterized by the presence of companies, such as Abbott Laboratories, Cardiva Medical Inc. (Haemonetics Corporation), Cordis Corporation (Cardinal Health Inc.), ENDOCOR GmbH & Co. KG, Merit Medical Systems Inc., Morris Innovative Inc., Teleflex Incorporated, Terumo Medical Corporation (Terumo Corporation), Transluminal Technologies LLC, Vasorum Ltd., etc.
• Challenges and Opportunities: The vascular closure devices market faces challenges such as stringent regulatory policies, which can delay product approvals and market entry. There is also a high cost associated with advanced technologies, limiting adoption in cost-sensitive markets. Moreover, the risk of complications such as infections and blood vessel damage pose a challenge to the market growth. However, these challenges present opportunities for innovation in developing safer and more effective closure devices. There is also a significant opportunity in emerging markets, where healthcare infrastructure improvements and increasing healthcare expenditure create a growing demand for advanced medical devices, which is driving the vascular closure devices market outlook.

VASCULAR CLOSURE DEVICES MARKET TRENDS:

Increasing Incidence of Cardiovascular Diseases

The vascular closure devices market is witnessing unprecedented growth as the incidence of cardiovascular diseases is steadily increasing globally. More patients are being diagnosed with coronary artery disease, heart attacks, and peripheral vascular disorders, which are triggering interventional procedures. With aging populations in developing and developed countries, more patients are receiving diagnostic and therapeutic catheterization procedures, thus generating high demand for effective closure solutions. As per the predictions of the World Health Organization (WHO), the number of individuals aged 60 and above will increase from 1.1 in 2023 to 1.4 billion by 2030. Moreover, clinics and hospitals are using vascular closure devices to minimize complications related to manual compression methods, particularly for patients who have high-risk cardiovascular diseases. This trend is being complemented by lifestyle-related conditions like obesity, diabetes, hypertension, and a sedentary lifestyle, which are aggregately causing increased rates of cardiovascular events. With the rising burden of heart disease, healthcare professionals are increasingly depending upon vascular closure devices to provide safe and successful post-procedure recovery.

Increased Use of Minimally Invasive Procedures

The need for vascular closure devices is being aggressively driven by the increasing use of minimally invasive cardiovascular procedures. Healthcare providers and patients are increasingly opting for catheter-based interventions such as stenting and angioplasty over open surgery due to shorter hospital stays, faster recovery periods, and lower risks of complications. Along with this trend, the demand for effective vascular closure devices is constantly on the rise, as they have a significant role in closing sites of arterial punctures after catheter-based procedures. Hospitals are implementing these devices to enhance procedural effectiveness and patient comfort, eliminating the use of cumbersome, time-consuming manual compression techniques. This has been prompted by continuous advances in interventional cardiology, where new procedures are being created that need efficient vascular access management. As minimally invasive interventions become more popular in both developed and developing healthcare markets, advanced closure devices are in high demand. IMARC Group predicts that the global minimally invasive surgery market is projected to attain USD 94.9 Billion by 2033.

Emerging Vascular Closure Technologies

The market for vascular closure devices is being driven by ongoing innovation in the technologies of the devices, which are making them safer, more effective, and easier to use. Companies are launching next-generation products that are being developed with better bioabsorbable material, minipuncture, and better seal mechanisms. These advancements are minimizing the risk of complications like bleeding, infection, and vascular injury and maximizing patient outcomes for recovery. Development and research initiatives are aimed at creating devices that are compatible with more patient anatomies and interventional procedures, which is broadening their usage in clinical practice. Hospitals and doctors are increasingly turning to these sophisticated solutions due to the fact that they are streamlining procedural workflows and lowering overall treatment expenses. With technological advancements continuing, the vascular closure device segment is increasing competition, compelling companies to continue innovating. In 2024, Haemonetics Corporation , a worldwide medical technology firm dedicated to providing cutting-edge solutions for improved patient results, revealed the complete market launch of its VASCADE MVP(R) XL mid-bore venous closure system. The VASCADE MVP XL system was launched for U.S. hospitals, representing the latest enhancement to Haemonetics' VASCADE(R) vascular closure systems, which incorporate advanced collapsible disc technology and a unique resorbable collagen patch aimed at facilitating swift hemostasis.

VASCULAR CLOSURE DEVICES MARKET GROWTH DRIVERS:

Greater Emphasis on Patient Comfort and Post-Procedural Recovery

The vascular closure devices sector is driven by the growing emphasis on enhancing patient comfort and speeding up post-procedural recovery. Manual compression, once the standard to close femoral artery punctures, is being linked with discomfort, increased bed rest duration, and heightened likelihood of patient dissatisfaction. Vascular closure devices, on the other hand, are delivering faster hemostasis, enabling patients to ambulate sooner and depart from the hospital sooner. This trend is in line with sweeping changes in healthcare that are focusing on patient-centered care and improved recovery pathways. Hospitals are evermore embracing closure devices as one of the measures in reducing patient length of stay and maximizing overall health care efficiency. The patients' demands for minimally invasive techniques that reduce pain and discomfort are also pushing the demand further. As patient satisfaction keeps becoming a vital indicator of health care quality, vascular closure devices are being evermore given priority in clinical practice globally.

Growth of Healthcare Infrastructure in Emerging Markets

The market for vascular closure devices is being boosted by the widespread growth of healthcare infrastructure in emerging economies. Nations in the Asia-Pacific, Latin American, and Middle Eastern regions are investing heavily in updating hospitals and gaining increased access to advanced interventional cardiology procedures. With increased healthcare spending and enhanced medical infrastructure, an increasing number of patients in these countries are seeking angioplasty and catheterization, which are necessitating efficient closure solutions. Governments and private healthcare organizations are placing greater emphasis on implementing advanced medical technologies to cater to increased cardiovascular treatment demands. This growth is providing manufacturers of vascular closure devices with the potential to enter new markets and build robust distribution channels. As education regarding cardiovascular well-being is on the increase and timely diagnosis is being encouraged, the use of closure devices is increasingly on the rise in these markets. This is assisting in the fact that the market is increasingly being supported by both established and developing healthcare systems.

Growing Clinical Evidence for Safety and Efficacy

The vascular closure device market is being supported by the increasing amount of clinical evidence that is proving their safety, reliability, and effectiveness when compared to standard manual compression techniques. Various studies and clinical trials are proving that vascular closure devices are decreasing time to hemostasis, decreasing complication rates, and allowing for quicker mobilization of the patient. This data is promoting doctors and hospitals to add closure devices as the standard of care in interventional cardiology procedures. Regulatory approvals are more and more being granted on the basis of these robust data sets, enabling manufacturers to increase product availability in multiple geographies. In addition, peer-reviewed studies are supporting confidence among the healthcare community, with physicians giving first priority to devices with documented outcomes for their patients. The expanding scientific evidence base is guaranteeing long-term confidence in these technologies, promoting uptake in various healthcare environments. As clinical evidence keeps mounting, vascular closure devices are becoming indispensable parts of contemporary cardiovascular therapy.

VASCULAR CLOSURE DEVICES INDUSTRY SEGMENTATION:

Breakup by Product:

• Passive Approximators
  • Collagen Plugs
  • Sealant or Gel-Based Devices
  • Compression-Assist Devices
• Active Approximators
  • Suture-Based Devices
  • Clip-Based Devices
• External Hemostatic Devices

Passive approximators accounts for the majority of the market share

The passive approximators segment is driven by the increasing demand for MI surgical techniques in the healthcare industry. These devices are designed to achieve hemostasis at vascular access sites without active compression, thereby reducing patient discomfort and recovery time. The advancements in material science and device engineering play a crucial role in enhancing the efficacy and safety of passive approximators, ensuring reliable closure of puncture sites. Additionally, the segment benefits from growing regulatory approvals and clinical validations supporting their use in various interventional procedures, which bolsters market acceptance and adoption. Moreover, healthcare providers' preference for devices that offer predictable outcomes and minimize procedural complications contributes to the segment's growth. Apart from this, the shift towards outpatient care settings, driven by cost-efficiency and patient convenience, further propels the demand for passive approximators. The segment also benefits from strategic collaborations and partnerships among industry players to expand product offerings and geographic reach, fostering market expansion.

Breakup by Access:

• Femoral Access
• Radial Access

Femoral access accounts for the majority of the market share

The femoral access segment is driven by the increasing complexity and volume of cardiovascular interventions requiring reliable arterial access. As medical procedures become more intricate, especially in fields like interventional cardiology and radiology, the femoral artery remains a preferred route due to its size and accessibility for delivering devices such as stents and catheters. Healthcare providers favor femoral access for its direct access to major vessels, facilitating comprehensive treatment strategies and minimizing procedural risks associated with alternative access sites. Moreover, advancements in imaging technologies like fluoroscopy and ultrasound enhance the precision of femoral artery access, ensuring safer and more effective procedures. Apart from this, the femoral access segment benefits from continuous innovation in closure devices designed specifically for this route. These devices aim to streamline post-procedural hemostasis, reducing complications such as bleeding and infection, which are critical factors in patient recovery and outcome success. Innovations include bioresorbable plugs, suture-based closure systems, and collagen-based sealants, which provide tailored solutions for varying patient anatomies and procedural requirements.

Breakup by Procedure:

• Interventional Cardiology
• Interventional Radiology/Vascular Surgery

Interventional cardiology accounts for the majority of the market share

The interventional cardiology segment is driven by the increasing prevalence of CVDs globally. Conditions such as coronary artery disease and myocardial infarction continue to rise due to aging populations, sedentary lifestyles, and unhealthy dietary habits. This growing disease burden necessitates advanced treatment options like percutaneous coronary interventions (PCI) and transcatheter aortic valve replacements (TAVR), driving demand for interventional cardiology procedures. Moreover, technological advancements in imaging modalities, stents, and catheters enhance procedural efficacy and safety, attracting both patients and healthcare providers towards these MI interventions. The segment also benefits from the expanding role of preventive cardiology, promoting early detection and intervention to mitigate disease progression and reduce the need for more invasive treatments.

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Hospitals accounts for the majority of the market share

The hospitals segment is driven by the increasing demand for specialized medical services and advanced treatments that require robust infrastructure and skilled healthcare professionals. Hospitals serve as primary centers for complex procedures and critical care, necessitating a wide range of medical devices, including imaging systems, surgical instruments, and patient monitoring equipment. This demand is further bolstered by the rising incidence of chronic diseases and age-related ailments, driving hospital admissions and the need for comprehensive medical interventions. Apart from this, technological advancements play a pivotal role in enhancing hospital capabilities, from telemedicine solutions that improve accessibility to advanced diagnostic tools that enable more accurate diagnoses and personalized treatment plans. The integration of electronic health records (EHRs) and digital health platforms also supports streamlined patient management and data-driven decision-making within hospital settings, contributing to operational efficiency and patient satisfaction.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest vascular closure devices market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The North America regional market is driven by the increasing prevalence of CVDs and the subsequent rise in vascular procedures. As one of the leading regions for healthcare innovation and adoption of advanced medical technologies, North America sees a high incidence of conditions like coronary artery disease and peripheral vascular disease, necessitating frequent interventions such as cardiac catheterizations and angioplasties. Vascular closure devices play a crucial role in these procedures, offering efficient hemostasis and reducing post-operative complications, which drives their widespread adoption in clinical practice. The North America regional market is further bolstered by robust technological advancements in vascular closure devices. Innovations such as bioresorbable implants, enhanced hemostatic agents, and improved deployment mechanisms are continually introduced, aiming to improve procedural outcomes and patient comfort. These technological advancements cater to the region's demand for state-of-the-art medical solutions, fostering a competitive market landscape where healthcare providers prioritize the latest advancements to enhance patient care.

Apart from this, the North America regional market is influenced by the stringent regulatory environment and favorable reimbursement policies. Regulatory bodies like the FDA (Food and Drug Administration) ensure the safety and efficacy of vascular closure devices through rigorous approval processes, instilling confidence among healthcare providers and patients. Concurrently, favorable reimbursement frameworks incentivize hospitals and healthcare facilities to adopt these devices, facilitating broader market penetration and sustained growth in the region.

COMPETITIVE LANDSCAPE:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the vascular closure devices include Abbott Laboratories, Cardiva Medical Inc. (Haemonetics Corporation), Cordis Corporation (Cardinal Health Inc.), ENDOCOR GmbH & Co. KG, Merit Medical Systems Inc., Morris Innovative Inc., Teleflex Incorporated, Terumo Medical Corporation (Terumo Corporation), Transluminal Technologies LLC, Vasorum Ltd., etc. ()
• Key players in the vascular closure devices market are actively engaged in strategic initiatives aimed at expanding their product portfolios and geographical presence. These initiatives often include mergers, acquisitions, and partnerships with other companies to leverage complementary strengths and accelerate innovation. Companies are focusing on developing next-generation closure devices that offer enhanced safety, efficacy, and patient comfort, thereby differentiating their offerings in a competitive market landscape. Additionally, significant investments in research and development (R&D) are directed towards advancing technology, such as the use of bioresorbable materials and improved delivery mechanisms, to address evolving clinical needs and regulatory requirements. Market leaders are also intensifying efforts to strengthen their distribution networks and market penetration strategies, particularly in emerging economies where there is a growing demand for MI procedures. Furthermore, there is a concerted effort among these players to streamline manufacturing processes and reduce production costs to maintain competitive pricing and improve profitability.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Vascular Closure Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Passive Approximators
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Collagen Plugs
    • 6.1.2.2 Sealant or Gel-Based Devices
    • 6.1.2.3 Compression-Assist Devices
  • 6.1.3 Market Forecast
• 6.2 Active Approximators
  • 6.2.1 Market Trends
  • 6.2.1 Key Segments
    • 6.2.1.1 Suture-Based Devices
    • 6.2.1.2 Clip-Based Devices
  • 6.2.3 Market Forecast
• 6.3 External Hemostatic Devices
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Access

• 7.1 Femoral Access
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Radial Access
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Procedure

• 8.1 Interventional Cardiology
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Interventional Radiology/Vascular Surgery
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by End-User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Ambulatory Surgical Centers
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

• 11.1 Overview
• 11.2 Drivers
• 11.3 Restraints
• 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Cardiva Medical Inc. (Haemonetics Corporation)
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 SWOT Analysis
  • 15.3.3 Cordis Corporation (Cardinal Health Inc.)
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 ENDOCOR GmbH & Co. KG
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Merit Medical Systems Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Morris Innovative Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Teleflex Incorporated
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Terumo Medical Corporation (Terumo Corporation)
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Transluminal Technologies LLC
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Vasorum Ltd.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio